StreetInsider.com News Articles

Form 4 Arcutis Biotherapeutics, For: Jul 15 Filed by: Peetz Christopher

Fri, 17 Jul 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260717/26784395.html

Form 4 Arcutis Biotherapeutics, For: Jul 15 Filed by: Peetz Christopher

Fri, 17 Jul 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260717/26784395.html

Form 3 Arcutis Biotherapeutics, For: Jul 15 Filed by: Peetz Christopher

Fri, 17 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260717/26784332.html

Form 3 Arcutis Biotherapeutics, For: Jul 15 Filed by: Peetz Christopher

Fri, 17 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260717/26784332.html

Form 4 Arcutis Biotherapeutics, For: Jul 15 Filed by: Welgus Howard G.

Fri, 17 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260717/26784260.html

Form 4 Arcutis Biotherapeutics, For: Jul 15 Filed by: Welgus Howard G.

Fri, 17 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260717/26784260.html

Form 8-K Arcutis Biotherapeutics, For: Jul 15

Thu, 16 Jul 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260716/26779973.html

Form 8-K Arcutis Biotherapeutics, For: Jul 15

Thu, 16 Jul 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260716/26779973.html

Arcutis adds Mirum Pharmaceuticals CEO Chris Peetz to its board

Thu, 16 Jul 2026 09:00:48 -0400

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the appointment of Christopher "Chris" Peetz to its board of directors, effective July 15, 2026, according to a company statement.

Peetz currently serves as co-founder and chief executive officer of Mirum Pharmaceuticals, a position he has held since the company's founding in 2018. He also serves as an entrepreneur-in-residence at Frazier Life Sciences.

Prior to Mirum, Peetz was chief executive officer of Flashlight Therapeutics, Inc. and previously served as chief financial officer and head of corporate development at Tobira, which was acquired by Allergan plc. He has also held roles at Jennerex Biotherapeutics, Onyx Pharmaceuticals, Abgenix,

Arcutis adds Mirum Pharmaceuticals CEO Chris Peetz to its board

Thu, 16 Jul 2026 09:00:48 -0400

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the appointment of Christopher "Chris" Peetz to its board of directors, effective July 15, 2026, according to a company statement.

Arcutis Expands Board of Directors with Appointment of Chris Peetz

Thu, 16 Jul 2026 09:00:00 -0400

WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in immuno-dermatology, today announced that Christopher “Chris” Peetz has been appointed to the Arcutis Board of Directors effective July 15, 2026.

“We are delighted to welcome Chris Peetz to our Board of Directors at a pivotal time for Arcutis,” said Frank Watanabe, president and chief executive officer of Arcutis. “Chris has built an impressive track record leading biopharmaceutical companies through periods of expansion, from advancing multiple products through development, to building commercial

Arcutis Expands Board of Directors with Appointment of Chris Peetz

Thu, 16 Jul 2026 09:00:00 -0400

Arcutis Expands Board of Directors with Appointment of Chris Peetz

Thu, 16 Jul 2026 09:00:00 -0400

Arcutis Expands Board of Directors with Appointment of Chris Peetz

Thu, 16 Jul 2026 09:00:00 -0400

Form 144 Arcutis Biotherapeutics, Filed by: Welgus Howard G.

Wed, 15 Jul 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260715/26774045.html

Form 144 Arcutis Biotherapeutics, Filed by: Welgus Howard G.

Wed, 15 Jul 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260715/26774045.html

Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

Wed, 15 Jul 2026 16:00:00 -0400

WESTLAKE VILLAGE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its second quarter 2026 financial results and provide a business update after the U.S. financial markets close on Wednesday, August 5, 2026. The Company will host a conference call and webcast at 4:30 p.m. ET that same day.

A live webcast of the call and related presentation materials will be available on the “Events” section of the Company’s website.

Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

Wed, 15 Jul 2026 16:00:00 -0400

A live webcast of the call and related presentation materials will be available on the “Events” section of the Company’s website.

Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

Wed, 15 Jul 2026 16:00:00 -0400

A live webcast of the call and related presentation materials will be available on the “Events” section of the Company’s website.

Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

Wed, 15 Jul 2026 16:00:00 -0400

A live webcast of the call and related presentation materials will be available on the “Events” section of the Company’s website.

Attovia Therapeutics names John Smither to board of directors

Wed, 15 Jul 2026 08:30:31 -0400

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company based in San Carlos, Calif., has appointed John W. Smither to its board of directors as an independent director and chair of the Audit Committee, according to a press release dated July 15, 2026.

Smither currently serves as chief financial officer of MBX Biosciences (Nasdaq: MBX) and as a senior advisor to Frazier Life Sciences. He previously held chief financial officer or interim chief financial officer roles at several biotech companies, including Arcutis Biotherapeutics (Nasdaq: ARQT).